Global Pharmaceutical Grade Nicotinamide Mononucleotide Market Growth 2023-2029

Global Pharmaceutical Grade Nicotinamide Mononucleotide Market Growth 2023-2029

The global Pharmaceutical Grade Nicotinamide Mononucleotide market size is projected to grow from US$ 508 million in 2022 to US$ 637.1 million in 2029; it is expected to grow at a CAGR of 3.3% from 2023 to 2029.

United States market for Pharmaceutical Grade Nicotinamide Mononucleotide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Pharmaceutical Grade Nicotinamide Mononucleotide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Pharmaceutical Grade Nicotinamide Mononucleotide is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Pharmaceutical Grade Nicotinamide Mononucleotide players cover GeneHarbor, Herbalmax, Shinkowa, EffePharm, Mirailab Bioscience, Bangtai Bio, Jindawei and Hongboyuan Life Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Nicotinamide mononucleotides play an important role in the energy production of human cells by participating in the intracellular synthesis of NAD (nicotinamide adenine dinucleotide, an important coenzyme in cellular energy conversion). Nicotinamide mononucleotide, which was originally present in the human body but decreases with age. Earlier experiments have shown that nicotinamide mononucleotide NMN increases NAD in the organs of laboratory rats, thus inhibiting ageing of nerves and blood vessels, and also improving the symptoms of diabetes.

LPI (LP Information)' newest research report, the “Pharmaceutical Grade Nicotinamide Mononucleotide Industry Forecast” looks at past sales and reviews total world Pharmaceutical Grade Nicotinamide Mononucleotide sales in 2022, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Grade Nicotinamide Mononucleotide sales for 2023 through 2029. With Pharmaceutical Grade Nicotinamide Mononucleotide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical Grade Nicotinamide Mononucleotide industry.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical Grade Nicotinamide Mononucleotide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical Grade Nicotinamide Mononucleotide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pharmaceutical Grade Nicotinamide Mononucleotide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical Grade Nicotinamide Mononucleotide and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical Grade Nicotinamide Mononucleotide.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Grade Nicotinamide Mononucleotide market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Concentration≥98%
Concentration＜98%

Segmentation by application
Health Products
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GeneHarbor
Herbalmax
Shinkowa
EffePharm
Mirailab Bioscience
Bangtai Bio
Jindawei
Hongboyuan Life Technology

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pharmaceutical Grade Nicotinamide Mononucleotide market?

What factors are driving Pharmaceutical Grade Nicotinamide Mononucleotide market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pharmaceutical Grade Nicotinamide Mononucleotide market opportunities vary by end market size?

How does Pharmaceutical Grade Nicotinamide Mononucleotide break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.